Optical coherence tomography: Has its time come?

Heart

Volumn 97, Issue 17, 2011, Pages 1361-1362

  Lindsay, Alistair C ^a   Viceconte, Nicola ^a   Di Mario, Carlo ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE APPROVAL; DRUG ELUTING STENT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MEDICAL RESEARCH; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; NEOINTIMA; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 80051558875     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.214825     Document Type: Editorial

References (19)

1. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12. (Pubitemid 27028713)
2. Kataiwa H, Tanaka A, Kitabata H, et al. Head to head comparison between the conventional balloon occlusion method and the non-occlusion method for optical coherence tomography. Int J Cardiol 2011;146:186-90.
3. Takarada S, Imanishi T, Liu Y, et al. Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv 2010;75:202-6.
4. Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003;89:317-20. (Pubitemid 36241548)
5. Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach. Heart 2009;95:1913-19.
6. Tanimoto S, Rodriguez-Granillo G, Barlis P, et al. A novel approach for quantitative analysis of intracoronary optical coherence tomography: high inter-observer agreement with computer-assisted contour detection. Catheter Cardiovasc Interv 2008;72:228-35.
7. Tahara S, Bezerra HG, Sirbu V, et al. Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial. Heart 2010;96:1574-8.
8. Suzuki Y, Ikeno F, Koizumi T, et al. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv 2008;1:168-73. (Pubitemid 351506553)
9. Inoue T, Shite J, Yoon J, et al. Optical coherence evaluation for everolimus-eluting stents at 8 months after implantation (Cooperative Study with Korea). Heart 2011;97:1379-84.
10. Teramoto T, Ikeno F, Otake H, et al. Intriguing peristrut low-intensity area detected by optical coherence tomography after coronary stent deployment. Circ J 2010;74:1257-9.
11. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
12. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
13. Räber L, Jüni P, Nüesch E, et al. Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for coronary revascularization (LESSON-1). Presented by: Stephan Windecker, MD, European Society of Cardiology Congress. Stockholm, Sweden, 2010. J Am Coll Cardiol 2011;57:2143-51.
14. Kereiakes DJ, Sudhir K, Hermiller JB, et al. Comparison of Everolimus-Eluting and Paclitaxel- Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovasc Interv 2010;3:1229-39.
15. Caixeta A, Lansky AJ, Serruys PW, et al. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel- Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovasc Interv 2010;3:1220-8.
16. Kim JS, Jang IK, Kim JS, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009;95:1907-12.
17. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010;55:976-82.
18. Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010;31:165-76.
19. Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009;2:1240-7.